Antimicrobial lipopeptide tridecaptin A1selectively binds to Gram-negative lipid II

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 41, 2016, Pages 11561-11566

  Cochrane, Stephen A ^a   Findlay, Brandon ^a   Bakhtiary, Alireza ^a   Acedo, Jeella Z ^a   Rodriguez Lopez, Eva M ^a   Mercier, Pascal ^a   Vederas, John C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antibiotic; Lipid II; Membrane pore; Peptide; Peptidoglycan

Indexed keywords

DODECYLPHOSPHORYLCHOLINE; LIPID; LIPOPOLYSACCHARIDE; NISIN; POLYPEPTIDE ANTIBIOTIC AGENT; TRIDECAPTIN A1; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; LIPOPEPTIDE; PEPTIDE; TRIDECAPTINS;

ARTICLE; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ESCHERICHIA COLI; IN VITRO STUDY; INNER MEMBRANE; LIPOGENESIS; MEMBRANE BINDING; MICELLE; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON MOTIVE FORCE; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; KINETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANTI-BACTERIAL AGENTS; CELL MEMBRANE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; KINETICS; LIPIDS; LIPOPEPTIDES; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; PEPTIDES; PROTON-MOTIVE FORCE;

EID: 84991503077     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1608623113     Document Type: Article

References (35)

1. O'Neill J (2014) Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. (Review on Antimicrobial Resistance, London).
2. Butler MS, Blaskovich MA, Cooper MA (2013) Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo) 66(10):571-591.
3. Roemer T, Boone C (2013) Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol 9(4):222-231.
4. Butler MS, Robertson AAB, Cooper MA (2014) Natural product and natural product derived drugs in clinical trials. Nat Prod Rep 31(11):1612-1661.
5. Antibiotic Resistance Project (2016) Antibiotics currently in clinical development. (The PEW Charitable Trusts, Philadelphia, PA).
6. Parachin NS, Franco OL (2014) New edge of antibiotic development: Antimicrobial peptides and corresponding resistance. Front Microbiol 5:1-7.
7. Tang W, van der Donk WA (2013) The sequence of the enterococcal cytolysin imparts unusual lanthionine stereochemistry. Nat Chem Biol 9(3):157-159.
8. Knerr PJ, van der Donk WA (2012) Chemical synthesis and biological activity of analogues of the lantibiotic epilancin 15X. J Am Chem Soc 134(18):7648-7651.
9. Cochrane SA, Vederas JC (2016) Lipopeptides from Bacillus and Paenibacillus spp.: A gold mine of antibiotic candidates. Med Res Rev 36(1):4-31.
10. Ling LL, et al. (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517(7535):455-459.
11. Hamamoto H, et al. (2015) Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat Chem Biol 11(2):127-133.
12. Cociancich S, et al. (2015) The gyrase inhibitor albicidin consists of p-aminobenzoic acids and cyanoalanine. Nat Chem Biol 11(3):195-197.
13. Shoji J, et al. (1978) Isolation of tridecaptins A, B and C (studies on antibiotics from the genus Bacillus. XXIII). J Antibiot (Tokyo) 31(7):646-651.
14. Lohans CT, et al. (2014) Biochemical, structural, and genetic characterization of tridecaptin A1, an antagonist of Campylobacter jejuni. ChemBioChem 15(2):243-249.
15. Cochrane SA, Lohans CT, van Belkum MJ, Bels MA, Vederas JC (2015) Studies on tridecaptin B (1), a lipopeptide with activity against multidrug resistant Gram-negative bacteria. Org Biomol Chem 13(21):6073-6081.
16. Cochrane SA, et al. (2014) Synthesis and structure-activity relationship studies of N-terminal analogues of the antimicrobial peptide tridecaptin A (1). J Med Chem 57(3):1127-1131.
17. Cochrane SA, Vederas JC (2014) Unacylated tridecaptin A1 acts as an effective sensitiser of Gram-negative bacteria to other antibiotics. Int J Antimicrob Agents 44(6):493-499.
18. Velkov T, Thompson PE, Nation RL, Li J (2010) Structure: Activity relationships of polymyxin antibiotics. J Med Chem 53(5):1898-1916.
19. Cochrane SA, Findlay B, Vederas JC, Ratemi ES (2014) Key residues in octyl-tridecaptin A1 analogues linked to stable secondary structures in the membrane. ChemBioChem 15(9):1295-1299.
20. Li T, Jiang L, Chen H, Zhang X (2008) Characterization of excitability and voltage-gated ion channels of neural progenitor cells in rat hippocampus. J Mol Neurosci 35(3):289-295.
21. Langsrud S, Sundheim G (1996) Flow cytometry for rapid assessment of viability after exposure to a quaternary ammonium compound. J Appl Bacteriol 81(4):411-418.
22. Bakker EP, Mangerich WE (1981) Interconversion of components of the bacterial proton motive force by electrogenic potassium transport. J Bacteriol 147(3):820-826.
23. Ahmed S, Booth IR (1983) The use of valinomycin, nigericin and trichlorocarbanilide in control of the protonmotive force in Escherichia coli cells. Biochem J 212(1):105-112.
24. Noll KS, Sinko PJ, Chikindas ML (2011) Elucidation of the molecular mechanisms of action of the natural antimicrobial peptide subtilosin against the bacterial vaginosisassociated pathogen Gardnerella vaginalis. Probiotics Antimicrob Proteins 3(1):41-47.
25. Molenaar D, Abee T, Konings WN (1991) Continuous measurement of the cytoplasmic pH in Lactococcus lactis with a fluorescent pH indicator. Biochim Biophys Acta 1115(1):75-83.
26. Breukink E, et al. (1999) Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286(5448):2361-2364.
27. Hsu ST, et al. (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 11(10):963-967.
28. Schneider T, et al. (2010) Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328(5982):1168-1172.
29. Breukink E, et al. (2003) Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J Biol Chem 278(22):19898-19903.
30. Saha SL, Van Nieuwenhze MS, Hornback WJ, Aikins JA, Blaszczak LC (2001) Synthesis of an orthogonally protected precursor to the glycan repeating unit of the bacterial cell wall. Org Lett 3(22):3575-3577.
31. Van Nieuwenhze MS, et al. (2002) The first total synthesis of lipid II: The final monomeric intermediate in bacterial cell wall biosynthesis. J Am Chem Soc 124(14):3656-3660.
32. Lebar MD, et al. (2013) Forming cross-linked peptidoglycan from synthetic gramnegative Lipid II. J Am Chem Soc 135(12):4632-4635.
33. Güntert P, Mumenthaler C, Wüthrich K (1997) Torsion angle dynamics for NMR structure calculation with the new program DYANA. J Mol Biol 273(1):283-298.
34. Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455-461.
35. Stewart JC (1980) Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104(1):10-14.